NCT07252076 PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa
| NCT ID | NCT07252076 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria |
| Condition | Pancreatic Ductal Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-07-17 |
| Primary Completion | 2026-12-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2025-07-17 with a primary completion date of 2026-12-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic cancer has a low survival rate largely due to late diagnosis and undetected liver metastases. Computed tomography (CT), the standard diagnostic tool, often misses occult metastases that are later discovered during surgery. Recent studies suggest that magnetic resonance imaging (MRI), especially with diffusion-weighted imaging (DWI), can better detect very small liver metastases and help avoid unnecessary surgery. However, MRI is not yet widely used in routine practice due to limited evidence and its selective application. This study proposes incorporating contrast-enhanced MRI and DWI into the diagnostic workflow to improve diagnostic accuracy and guide more effective treatment decisions for patients with pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: * Male or female patients over 18 years of age. * Patients with a new cytological or histological diagnosis of PDAC. * A CT scan demonstrating pancreatic disease and meeting the minimum criteria for the imaging assessment of pancreatic gland tumors (see section 4.6, study procedures). * An MRI performed no later than 3 weeks after the CT scan, also meeting the minimum radiological criteria (see section 4.6, study procedures). * No prior treatment for pancreatic disease. * Patients able to receive and understand the study information and to provide written informed consent duly signed by both the patient and the investigator. Exclusion Criteria: * Signs of metastatic disease on the initial CT scan (hepatic, pulmonary, distant lymph node, peritoneal carcinomatosis, or other organ involvement).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07252076 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Ductal Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07252076 currently recruiting?
Yes, NCT07252076 is actively recruiting participants. Contact the research team at clinicaltrialcenter@ospedale.al.it for enrollment information.
Where is the NCT07252076 trial being conducted?
This trial is being conducted at Alessandria, Italy.
Who is sponsoring the NCT07252076 clinical trial?
NCT07252076 is sponsored by Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria. The trial plans to enroll 120 participants.